Timo L.
- Country
- The Netherlands
- Department
- Cardiology
Research Overview
- Phase 3, Multicenter, Placebo‑Controlled Study of Intranasal Etripamil for Rapid Ventricular Rate Control in Atrial Fibrillation (ReVeRA‑301)
- Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo controlled randomized clinical trial. RITA-MI 2
- DUTCH Weight Control in Atrial Fibrillation Study
Data & Insights
Has run more than one trial at 60 of 439 partner sites.
Specializations
Cardiovascular Disorders
This investigator specializes in treating various forms of atrial fibrillation and conducting research on preventing cardioembolic events. Their work encompasses innovative approaches in cardiac rhythm management and stroke prevention strategies.
- Atrial Fibrillation Management
- Stroke Prevention
- Cardiac Embolism
Metabolic Conditions
The investigator focuses on treating hypertriglyceridemia and its relationship with atherosclerotic cardiovascular disease. Their research extends to innovative lipid management approaches and cardiovascular risk reduction strategies.
- Lipid Disorders
- Atherosclerosis Treatment
- Cardiovascular Risk Management
Acute Cardiac Care
Specialized expertise in treating ST-elevation myocardial infarction with particular focus on left ventricular function assessment and novel therapeutic interventions for acute myocardial infarction.
- Myocardial Infarction Treatment
- Cardiac Function Assessment
- Emergency Cardiac Care
Metabolic-Cardiac Interface
The investigator studies the intersection of obesity and cardiac conditions, particularly focusing on the relationship between weight management and persistent atrial fibrillation. Their work explores innovative therapeutic approaches for patients with concurrent metabolic and cardiac conditions.
- Obesity Management
- Rhythm Control Strategies
- Metabolic-Cardiac Interventions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.